CHICAGO (Reuters) -An experimental Alzheimer’s drug developed by Eli Lilly (NYSE:LLY) and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.…Read More
Lilly drug slows Alzheimers by 35 bolstering treatment approach By Reuters
